What to Know About BA.2, a New Omicron Variant
Even as SARS-CoV-2 gets better at spreading and evading some of the immune protection that people have built through infections or vaccination, new variants inevitably arise. The latest is BA.2,…
Even as SARS-CoV-2 gets better at spreading and evading some of the immune protection that people have built through infections or vaccination, new variants inevitably arise. The latest is BA.2,…
The Pennsylvania Department of Health deployed a state-directed health care strike team to help relieve strain on health care workers and hospitals during the COVID-19 pandemic, according to a statement…
As the Supreme Court weighs the high-profile case that could unwind Roe v. Wade—and, with it, the Constitutional right to abortion—conservative state lawmakers are introducing a wave of new bills…
Tarpeyo (budesonide) is now available to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) of at…
Opioid prescriptions have fallen in recent years, after health care providers became more aware of the risks of overdoses and the federal government tightened prescribing rules. While opioids were dispensed…
Lilly has decided to discontinue the phase 3 development program for baricitinib in adults with active systemic lupus erythematosus. The decision was made based on data from 2 pivotal phase…
WASHINGTON — The Environmental Protection Agency announced a series of enforcement actions Wednesday to address air pollution, unsafe drinking water and other problems afflicting minority communities in three Gulf Coast…
Neutralizing antibody levels against the Omicron variant declined 6 months after a booster dose of the Moderna COVID-19 vaccine but remained detectable in all participants, according to new data published…
Moderna reported today the first data on how well its currently authorized vaccine and booster hold up against the Omicron variant, which quickly dominated new infections around the world after…
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for risdiplam for use in presymptomatic infants less than 2 months of age…